3SOF

9:53AM Spherix Wins Indiana State Parks Reservations Contract (SPEX) 2.35 +0.18 : Co announces it has won a 4-year contract worth about $4.4 mln to continue operating the central reservation system for Indiana State Parks. Indiana Governor Mitch Daniels and Dept of Natural Resources Director Kyle Hupfer announced the new contract late last week. Co says it had successfully completed its first 4-year contract and won the competitive re-bid.

This small float stock should move on this news today

Spherix Agrees to $6 Million Settlement to Drop Protest Over Award of National Park Service Contract
PR Newswire - October 26, 2006 8:26 AM ET
 
 
Spherix Incorporated (Nasdaq: SPEX) has agreed to a $6 million settlement to end its longstanding legal dispute with the U.S. Department of Agriculture over the government's award of the National Recreation Reservation Service contract to ReserveAmerica, a Ticketmaster subsidiary.

Spherix officials are pleased with the settlement, which will provide additional finances to allow the Firm to move forward with important projects while eliminating the legal fees, effort, and uncertainty that would persist were the four-year dispute to continue.

"This is good and very welcome news," said Spherix President and CEO Richard Levin. "Financially, the settlement readily achieves fair compensation for the Company and its shareholders, and will permit us to focus on the future. It will allow us to invest more time, resources, and money in developing new products we've had planned for our reservations business, which will allow us to be even more competitive in the state and local markets where the potential for steady growth is much greater. We're happy to be able to move positively and confidently into the future."

InfoSpherix, the Company's wholly-owned subsidiary that operates its ReserveWorld business line, won two more state parks reservation contracts in the past month, and is a subcontractor on a third, smaller winning state park proposal. The settlement is expected to strengthen and expand InfoSpherix's offerings in the state and county markets, and potentially in the commercial recreation market, with advanced tools for camping and boating reservations, point-of-sale transactions, online ticketing, property management, facility rentals, and other park support functions.

Background:

In the past three years, the USDA Forest Service has twice awarded the contract for the National Recreation Reservation Service to ReserveAmerica. Both times, Spherix lodged and won protests of the award, with the Government Accountability Office finding flaws in the procurement that unfairly disadvantaged Spherix in the competitive evaluation of proposals.

Spherix and ReserveAmerica have held separate contracts to operate reservation services for the National Park Service and the Forest Service, respectively, since 1997. In 2002, the U.S. Office of Management and Budget required that the two contracts be bundled into one, under the auspices of the Forest Service. The two companies have continued to operate their respective contracts throughout the succeeding procurements, protests, and legal challenges. With the settlement in place, Spherix is expected to continue operating the National Park Reservation Service until Ticketmaster/ReserveAmerica is able to deploy its reservations system over the combined inventory of national parks, recreation areas, historical sites, and other reservable federal lands.

GREAT CALL !!     MORE NEWS.............

Press Release   Source: Spherix Incorporated

Naturlose(R) Dosage Test Shows Positive Effect
Thursday October 26, 11:32 am ET
Spherix to Begin Recruiting Participants for Phase 3 Diabetes Trial

BELTSVILLE, Md., Oct. 26 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX - News) has successfully completed its dose range-finding study, allowing it to continue with its Phase 3 clinical trial of Naturlose as a treatment for type 2 diabetes (see Spherix news releases dated May 23, 2006, and August 10, 2006). The tests were done on human subjects to establish the appropriate dosage and timing to be used in the upcoming trial. The Company will now recruit patients for the trial, which will take place in Australia and the United States. Company officials expect that the first participants will begin the Phase 3 clinical trial by April 2007.

ADVERTISEMENT
"The test results so far have been positive," said Spherix President Richard Levin. "Not only did they determine the dose and timing for the trial, but the results corroborate what we have seen in smaller, previous tests -- that Naturlose has a beneficial effect on modulating postprandial blood glucose, an important factor in the treatment of Type 2 diabetes. We are moving forward with confidence that we have a scientifically sound foundation on which to complete the Phase 3 trial, and to anticipate a favorable outcome."

Levin said that the Company's recently announced settlement of a contract dispute (see Spherix's PR released earlier today) in its reservations business will bolster its financial ability to support Naturlose. In that settlement, Spherix agreed to accept $6 million to end the longstanding legal dispute over the award of the National Recreation Reservation Service contract. Spherix intends to use a portion of that payment to support its efforts to develop Naturlose as a marketable product. Spherix believes these funds, along with existing cash, will ensure its ability to complete the Phase 3 clinical trial.

If the Phase 3 trial establishes that Naturlose is an effective treatment for diabetes, Spherix will prepare a New Drug Application (NDA) for presentation to the Food and Drug Administration (FDA). FDA approval would give Spherix the right to market Naturlose as a diabetes drug. Naturlose has already been shown to be safe.

Certain statements contained herein are "forward looking" statements as defined in the Private Securities Litigation Reform Act of 1995. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied. Factors that could cause actual results to differ materially from those expressed or implied include, but are not limited to, those discussed in filings by the Company with the Securities and Exchange Commission, including the filing on Form 8-K made on March 3, 1999.

Under its motto, "A World of Solutions," Spherix's mission is to create value and increase shareholder wealth through innovations that benefit our clients and the human condition. Spherix offers innovations in information technology, knowledge management, and biotechnology.

This turned out to be a nice daytrade In 15,000 @ 1.59 sold 1/2 @ 2.54. I will sell the rest before the market closes. This rarely trades up two days in a row. Hope some of you got in this morning.

Yes...A nice little pop there!
Good going guys.....send out applaud....

SPEX is stepping......Impressive !
In the short term, this one could easily test its old resistance @ $3.50, and I wouldn't rule out a surge back to $4.00 in the next week or two.
SPEX has an "all natural" sugar substitute called "Tagalose" that apparently is gaining some interest, particularly on the west coast of the US.

52wk Range: 1.18 - 5.85
Volume: 749,141
Avg Vol (3m): 71,451.6

Technicals
Close Above the 13-day MA
Percentage Gainer

Last Price Quote is:
31.66%above 13-day MA
44.32%above 50-day MA
RS Rating: 98 

Fundamentals
Key Data:
Market Cap (M): $17.63 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: N/A

Shares Outstanding: 12.10M
Float: 9.53M
% Held by Insiders4: 20.92%
% Held by Institutions4: 5.90%

Excellent TA.

The fundamentals definetly check out on SPEX.  The market cap is a tiny $33MM with a $24MM EV, with cash in the bank and little debt.  They are basically running breakeven.

Latest filing summarizes it's bright spots:

BELTSVILLE, MD, Spherix Incorporated (NASDAQ/SPEX) reported revenue of $7.3 million and $20.8 million for the three-months and nine-months ended September 30, 2006, up 8% over the same periods in 2005. The increase between years is the result of a new government reservation contract, which the Company began performing early in 2006. During the three- and nine-month periods, the Company's R&D costs were $441,000 and $723,000, respectively; an increase of $400,000 and $511,000, respectively, over the same periods of the prior year. The increased expenditures resulted from the escalation of activity relating to the Phase 3 clinical trial of Naturlose as a treatment for type 2 diabetes. A range-finding study was successfully completed, and provided encouraging early signs (see Spherix news release dated October 26, 2006). With the increase in R&D expenditures between years, Company's net income decreased by $295,000 for the quarter, but remained $256,000 above the prior year's net loss for the year to date

March will be huge for  SPEX.....Keep an eye on it

SPEX is starting to move up......watch it run after it breaks $2

"SPEX" Threads have been Merged.
Please use the search before starting new threads on a Stock Pick.
Chances are a thread already exist.
So why not post whatever you have to comment about on that pick to that thread.
"Simplicity" My fellow traders.                                   
All history on a stock pick in 1 thread is awesome.                                
Just trying to get threads together,so we don't have a numerous amount floating around on the same stock.            
Thank You....and good luck with all your trades....make some $$$            

SPEX is acting like it wants to breakout from under $2. If it does, there is no resistance ntil it reaches $2.6

TIC TOC TIC TOC....Explosion just ahead. Radar this gem

Strong performance by SPEX in this horrible market this week. Once SPEX  breaks $2 it will be off to the races.....

http://stockcharts.com/charts/gallery.html?SPEX

Take a look at what happened in December 2005...lower chart...an even bigger explosion is coming up

FACT:

SPEX IS THE ONLY PROFITABLE BIOTEC WITH LESS THAN $30M MARKET CAP ENTERING PHASE 3 CLINICAL TRIALS FOR A POTENTIALLY BLOCKBUSTER DRUG...

On December 6 and 7, 2005 SPEX went from $1.26 to $5.85 with over 20M shares traded, or twice the float, when it announced that the FDA had approved Naturlose's Phase 1 and 2 clinical data allowing the company to pursue Phase 3 clinical trials (see lower chart):

http://stockcharts.com/charts/gallery.html?spex

With Phase 3 Naturlose patient recruiting in Australia and the US almost complete, SPEX will likely update the investment community about the official launch of this pivotal phase clinical trials ....very ....very soon.

This means that another explosion in pps and shares traded is just around the corner.

Regarding Phase I and Phase 2 clinical trials, the FDA agreed that:

- Naturlose has an excellent safety profile

- Naturlose taken before food consumption prevents an increase in glucose levels in the blood

- Patients taking Naturlose lost weight and experienced a significant increase in HDL or good cholesterol

Naturlose is a naturally occurring compound found in milk and various fruits and as such it does not have harmful side effects and limitations like Starlix, glucotrol, insulin, and other products in the market do.


SPEX INVESTMENT HIGHLIGHTS:

- Market cap: $28M

- Est. 2007 Revenues: $28M

- Float: 9M

- Cash: $10M

- No long term debt

- PROFITABLE


SPEX's Naturlose is also currently being tested at University of Maryland as an anti-gingivities and anti-plaque agent to be used in toothpaste, mouthwash, and sugarless chewing gum.

Naturlose is also being tested in many important applications such as the preservation of critical blood components.

Unlike other biotecs, SPEX funds its BioSpherix Division's clinical development through strong earnings coming from its InfosPherix, information services division. InfoSpherix's backlog has increased from $11M to $75M within the last 12 months.

SPEX has been profitable or break-even the last 2 quarters due to InfoSpherix's strong increase in backlog and new contracts despite a huge jump in R&D expenses to fund its clinical trials.

http://finance.yahoo.com/q/is?s=SPEX

Tagatose/Naturlose is the newest member of the sweeteners category (potential Equal and Splenda replacement). Tagatose has been granted GRAS (Generally Recognized As Safe) status by the FDA allowing it to be included in foods as a sweetener.

On December 15, 2006, SPEX announced that tagatose was formally approved "as a novel food ingredient" by the European Union (EU) permitting the use of the sweetener in a wide range of of products from soft drinks, to candy, to tooth paste. The approval followed approval by South Korea, Australia, New Zealand, Brazil and other countries..


ABOUT SPEX:


Spherix Incorporated (Nasdaq: SPEX) engages in the provision of information services, as well as in the biotechnological research and development activities in the United States. It operates through two divisions, InfoSpherix and BioSpherix.

InfoSpherix division designs and operates contact centers providing information management and other services for campgrounds, golf courses, and other parks through its ReserveWorld business line.

BioSpherix division engages in the development of proprietary products for commercial applications. It offers tagatose, a sweetener, under the brand name Naturlose. The company has a license agreement with Arla Foods Ingredients to manufacture, market, and distribute tagatose as a food and beverage ingredient.

SPEX's NATURLOSE IS A POTENTIALLY MULTY-BILLION BLOCKBUSTER DRUG


NATURLOSE PHASE 3 CLINICAL TRIALS TO CONTROL GLUCOSE IN DIABETES 2 PATIENTS

On October 26, 2006, SPEX announced:

That it has successfully completed its dose range-finding study, allowing it to continue with its Phase 3 clinical trial of Naturlose as a treatment for type 2 diabetes (see Spherix news releases dated May 23, 2006, and August 10, 2006).

The tests were done on human subjects to establish the appropriate dosage and timing to be used in the upcoming trial. The Company will now recruit patients for the trial, which will take place in Australia and the United States.

Company officials expect that the first participants will begin the Phase 3 clinical trial by April 2007.

"The test results so far have been positive," said Spherix President Richard Levin. "Not only did they determine the dose and timing for the trial, but the results corroborate what we have seen in smaller, previous tests -- that Naturlose has a beneficial effect on modulating postprandial blood glucose, an important factor in the treatment of Type 2 diabetes. We are moving forward with confidence that we have a scientifically sound foundation on which to complete the Phase 3 trial, and to anticipate a favorable outcome."

CEO Levin said that the Company's recently announced settlement of a contract dispute in its reservations business will bolster its financial ability to support Naturlose. In that settlement, Spherix agreed to accept $6 million to end the longstanding legal dispute over the award of the National Recreation Reservation Service contract. Spherix intends to use a portion of that payment to support its efforts to develop Naturlose as a marketable product. Spherix believes these funds, along with existing cash, will ensure its ability to complete the Phase 3 clinical trial.

In December 2005, regarding Phase I and Phase 2 clinical trial data, the FDA agreed that:

- Naturlose has an excellent safety profile

- Naturlose taken before food consumption prevents an increase in glucose levels in the blood

- Patients taking Naturlose lost weight and experienced a significant increase in HDL or good cholesterol

Naturlose is a naturally occurring compound found in milk and various fruits and as such it does not have harmful side effects and limitations like Starlix, glucotrol, insulin, and other products in the market do.

http://www.drugnewswire.com/7930/

NATURLOSE FOR USE AS AN ANTI-GINGIVITIS AND ANTI-PLAQUE INGREDIENT.

SPEX is proceeding with initial plans to enter the toothpaste market by offering Naturlose(R) as a natural toothpaste ingredient that fights gingivitis and plaque, while also being safe enough for children to use.

Based on its previous tests showing that Naturlose has the potential to inhibit dental plaque development.

In November, 2006, SPEX announced that it has contracted with the Center for Clinical Studies at the University of Maryland's School of Dentistry in Baltimore to conduct a six-month clinical trial with 80 participants to test Naturlose-containing toothpaste for anti-gingivitis and anti-plaque efficacy.

http://www.medicalnewstoday.com/medicaln...


NATURLOSE AS AN AGENT TO IMPROVE BLOOD TRANSFUSIONS:

On November 3, 2005 SPEX announced that it has signed a Naturlose License Agreement with the Albert Einstein College of Medicine to seek products to enhance blood transfusion technology

Under its license, the BioSpherix Division of SPEX gains the rights to Naturlose-containing products and processes under development at Einstein that enhance storage lifetimes of medicinal proteins, including blood components; Spherix will pay royalties to Einstein on sales of any forthcoming patented products or processes.

In its first annual report on the research effort, Einstein said that Naturlose " ... is an especially promising stability-enhancing additive to a wide range of dry protein formulations (which includes the essential blood component, hemoglobin)."

http://www.biotech-intelligence.com/html...